Last Updated 29 December 2015
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically important gram-positive pathogen found in both the hospital and outpatient settings. The recent approvals of oritavancin (The Medicine Company’s Orbactiv), dalbavancin (Allergan’s Dalvance/Xydalba), and tedizolid (Bayer HealthCare/Merck’s Sivextro) have greatly increased treatment options for MRSA infections, making the hospital-treated MRSA market highly competitive. Within this crowded space, new agents will need to demonstrate improvement over current therapies and justify their premium pricing in light of significant competition, including generics. This report provides a comprehensive overview and analysis of the epidemiology, patient populations, and current and emerging medical practice and therapies for MRSA in the major pharmaceutical markets. The insights presented in this report are derived from primary and secondary research, company presentations and sales data, as well as detailed interviews with recognized key opinion leaders (KOLs). This report includes a 2014-2024, epidemiology-based, annualized, bottom-up forecast of current and emerging MRSA therapies in the major pharmaceutical markets.
Questions Answered in This Report:
- There are many agents in the HT-MRSA market, and therefore understanding the positioning of these current therapies in the hospital setting is essential for identifying physicians’ needs in this market. What do experts think about currently available therapies for MRSA, and how are they currently used in hospital settings?
- During the forecast period, at least eight new antibiotics are expected to launch, and key MRSA drugs such as linezolid and daptomycin will also lose patent protection. Understanding the dynamics of the HT-MRSA market is key to positioning a company’s agent in this highly competitive space. Which currently available and emerging MRSA therapies are poised for commercial success over the 2014-2024 forecast period?
- The HT-MRSA infection market will be crowded with more than 20 antibiotics available during the forecast period. Identifying unmet needs in underserved patient populations is key to developing appropriate strategies to increase uptake and achieve commercial success. What are the areas of greatest unmet need for the MRSA market, and how will emerging brands address these unmet needs?
- Public health agencies have always considered controlling and preventing MRSA infection as one of their top priorities and have developed a series of policies accordingly. Given the recent positive impact of these policies, such as antimicrobial stewardship, these agencies are expected to implement more controls over MRSA prevention and treatment strategies, thus directly affecting the development of new antibiotics and sales of current antibiotics. How will changing regulatory policies regarding antibiotic usage and antibiotic resistance affect the development and positioning of novel antibiotics for MRSA?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 30 country-specific interviews with gastroenterologists and infectious diseases specialists.
Epidemiology: Diagnosed events of the MRSA population by country and indication, including hospital and community-acquired MRSA.
Population segments in market forecast: Complicated skin and skin structure infections (cSSSIs), bloodstream infections (BSIs), complicated intra-abdominal infections (cIAIs), urinary tract infections (UTIs), and nosocomial pneumonia (NP).
Emerging therapies: Phase III: 5 drugs; Phase II: 7 drugs; recent launch: 3 drugs.
Kristin Dorfman, M.P.H., M.S.